Group 1 - Altec Automotive Technology Co., Ltd. (stock code: 300825) has experienced a decline for five consecutive trading days, with a cumulative drop of -3.05% [1] - In the first quarter of this year, China Europe Fund's China Europe New Blue Chip Mixed A Fund entered Altec's top ten shareholders as a new investor [1] - The year-to-date return of the China Europe New Blue Chip Mixed A Fund is 6.57%, ranking 2020 out of 4527 in its category [1] Group 2 - The performance of the China Europe New Blue Chip Mixed A Fund shows a year-to-date return of 6.57%, with a quarterly return of -0.86% and a monthly return of 3.80% [2] - The fund's performance is compared to the average of its peers, which has a year-to-date return of 7.76% [2] - The fund manager, Zhou Weiwen, has extensive experience, having managed various funds since 2006, and currently oversees multiple funds at China Europe Fund Management [3][4] Group 3 - The other fund manager, Feng Ludan, has been with China Europe Fund Management since 2016 and has managed the China Europe New Blue Chip Flexible Allocation Mixed Fund since October 2021 [5] - Feng Ludan's managed funds have shown significant returns, with the China Europe Digital Economy Mixed Fund achieving a return of 67.65% since September 2023 [5]

Core Viewpoint - The trend of transitioning from single fund manager models to multi-manager collaborative models is becoming increasingly prominent in the public fund industry, as evidenced by recent appointments at various funds [1][5][7]. Group 1: Fund Manager Appointments - Zhao Lei has been appointed as a co-manager for the China Europe Medical Health Mixed Fund alongside Ge Lan [1][2]. - Jin Xuwei has been appointed as a co-manager for the China Europe Value Growth Mixed Fund with Wang Jian [3]. - Song Ting has been appointed as a co-manager for the China Europe National Index 2000 Enhanced Fund with Qian Yating [4]. - Su Wenjie has been appointed as a co-manager for the GF Growth Power Three-Year Holding Mixed Fund with Zheng Chengran [5][6]. Group 2: Industry Trends - In the past year, a total of 29 products under China Europe Fund have adopted the "co-management" approach, indicating a clear shift towards team-based management [5]. - The transition from individual to team-based management is recognized as a significant transformation direction in the public fund industry [7]. - Regulatory bodies have emphasized the importance of team-based management structures in the public fund industry, as highlighted in the guidelines issued in 2022 and 2023 [7].

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown positive growth in recent months and has a significant concentration in its top ten stock holdings [1][3] - As of July 3, 2025, the latest net value of the fund is 1.6642 yuan, reflecting a growth of 1.50%. The fund's one-month return is 1.53%, six-month return is 14.38%, and year-to-date return is 10.32% [1] - The fund's top ten stock holdings account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%), WuXi AppTec (9.95%), and Mindray Medical (5.21%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund manager, Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in October 2014 [2]

Group 1 - Shandong Gold Mining Co., Ltd. experienced a stock price drop of 2.17% on July 3, 2023, and is primarily engaged in the non-ferrous metal mining and selection industry [1] - The company was established in 2000 and is located in Jinan, with a registered capital of 44,734.29525 million RMB [1] - Central European Fund's Central European Value Select Mixed A has entered the top ten shareholders of Shandong Gold, marking a new investment in the first quarter of this year, with a year-to-date return of 9.66% and a ranking of 469 out of 2301 in its category [1] Group 2 - Yuan Weide is the fund manager of Central European Value Select Mixed A, with a background in financial engineering, TMT, new energy, technology, and consumer sectors [3][4] - Yuan Weide has been with Central European Fund since July 2015 and has held various positions, including managing multiple funds since December 2016 [3][4] - The total assets under Yuan Weide's management amount to 10.267 billion RMB, with a return of 113.34% during his tenure [4]

Group 1 - The core viewpoint of the article highlights the performance of the China Europe Medical Innovation Stock A fund, which has shown significant growth in recent months and year-to-date [1] - As of June 30, 2025, the latest net value of the fund is 1.3751 yuan, reflecting a growth of 1.60% [1] - The fund's one-month return is 3.33%, six-month return is 32.25%, and year-to-date return is also 32.25%, with respective rankings of 276 out of 1029, 29 out of 997, and 30 out of 997 in its category [1] Group 2 - The top ten holdings of the China Europe Medical Innovation Stock A fund account for a total of 75.62%, with major investments in companies such as WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 4.675 billion yuan [1] - The fund manager, Ms. Ge Lan, has a background in biomedical engineering and has held various positions in research and fund management since joining China Europe Fund Management in 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年6月23日消息，中欧医疗健康混合A(003095) 最新净值1.6675元，增长1.10%。该基金近1个 月收益率1.79%，同类排名725|2535；近3个月收益率5.36%，同类 ...

金融界2025年6月23日消息，中欧医疗创新股票A(006228) 最新净值1.3629元，增长2.04%。该基金近1个 月收益率6.36%，同类排名28|561；近6个月收益率28.48%，同类排名18|548；今年来收益率31.07%，同 类排名17|550。 中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 ...

Group 1 - The core viewpoint of the news is that the China Europe Medical Innovation Stock A (006228) has experienced a decline of 2.62% on June 19, with a cumulative drop of 9.02% over the last five trading days, indicating a downward trend in its performance [1] - As of the end of 2024, the fund has a total size of 4.675 billion yuan and has achieved a cumulative return of 33.78% since its establishment in February 2019 [1] - The holder structure shows that institutional investors hold 0.23 million shares, accounting for 0.61% of the total shares, while individual investors hold 38.37 million shares, making up 99.39% of the total [1] Group 2 - The current fund manager, Ms. Ge Lan, has a Ph.D. in Biomedical Engineering from Northwestern University and has extensive experience in the investment management field, having joined China Europe Fund Management in October 2014 [2] - Ms. Ge has managed several funds, including the China Europe Medical Health Mixed Securities Investment Fund since September 29, 2016, and has held various managerial positions in other funds [2] Group 3 - As of March 31, 2025, the top ten holdings of China Europe Medical Innovation Stock A account for a total of 75.62%, with the largest positions being WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and WuXi AppTec (9.60%) [3]

Group 1 - The core viewpoint of the news is that the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A has experienced a decline of 1.31% on June 19, with a cumulative drop of 4.73% over the past five trading days [1] - The fund was established in August 2024 with a total size of 0.13 billion yuan and has achieved a cumulative return of 2.92% since inception [1] - As of the end of 2024, institutional investors hold 0.10 billion shares, accounting for 91.94% of the total shares, while individual investors hold 0.01 billion shares, accounting for 8.06% [1] Group 2 - The current fund manager, Song Weiwei, has a background in research and investment management, having served in various roles at China Europe Fund Management Company since 2024 [2] - Song Weiwei has managed multiple funds, including the China Europe CSI Robotics Index Fund and the China Europe CSI Chip Industry Index Fund, among others, since early 2024 [2] Group 3 - As of March 31, 2025, the top ten holdings of the China Europe CSI All-Share Healthcare Equipment and Services Index Fund A account for a total of 41.48%, with major holdings including Mindray Medical (9.10%), Aier Eye Hospital (7.77%), and United Imaging Healthcare (6.36%) [3]